| scholarly article | Q13442814 |
| P50 | author | Yohann Foucher | Q42879101 |
| Jean-Paul Soulillou | Q43024331 | ||
| P2093 | author name string | Sophie Brouard | |
| Magali Giral | |||
| Anne Moreau | |||
| Emilie Dugast | |||
| Michael Mengel | |||
| Wilfried Gwinner | |||
| Karine Renaudin | |||
| Jacques Dantal | |||
| Claire Usal | |||
| Joanna Ashton-Chess | |||
| Helga Smit | |||
| Ludmilla Le Berre | |||
| Marina Guillet | |||
| Richard Danger | |||
| Vojislav Jovanovic | |||
| Hoa Le Mai | |||
| Maud Racapé | |||
| P2860 | cites work | Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 |
| Progressively impaired proteasomal capacity during terminal plasma cell differentiation | Q30476988 | ||
| Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome | Q32067271 | ||
| Proteasome inhibition suppresses essential immune functions of human CD4+ T cells | Q33316357 | ||
| Abrogation of anti-HLA antibodies via proteasome inhibition | Q33384617 | ||
| Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response | Q34078561 | ||
| Development of the proteasome inhibitor Velcade (Bortezomib). | Q34327233 | ||
| Extrarenal effects on the pathogenesis and relapse of idiopathic nephrotic syndrome in Buffalo/Mna rats | Q34788131 | ||
| The proteasome: structure, function, and role in the cell | Q35124091 | ||
| Humoral theory of transplantation | Q35142603 | ||
| Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection | Q36078696 | ||
| The proteasome immunosubunit multicatalytic endopeptidase complex-like 1 is a T-cell-intrinsic factor influencing homeostatic expansion | Q36483688 | ||
| The Fischer-Lewis model of chronic allograft rejection--a summary | Q36578958 | ||
| Tribbles-1 as a novel biomarker of chronic antibody-mediated rejection. | Q36677655 | ||
| Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies | Q36736625 | ||
| An altered T cell repertoire in MECL-1-deficient mice | Q40278161 | ||
| A proteasome inhibitor effectively prevents mouse heart allograft rejection | Q43690667 | ||
| Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells | Q44987437 | ||
| Dipeptide boronic acid, a novel proteasome inhibitor, prevents islet-allograft rejection | Q45022042 | ||
| De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. | Q45100299 | ||
| Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production | Q46270888 | ||
| The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis | Q46549173 | ||
| Dampening Ab responses using proteasome inhibitors following in vivo B cell activation | Q46769248 | ||
| Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial | Q46825301 | ||
| Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation | Q46990641 | ||
| Expression profiling on chronically rejected transplant kidneys | Q47684367 | ||
| The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. | Q47700046 | ||
| Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies | Q47949686 | ||
| Predicting kidney graft failure by HLA antibodies: a prospective trial. | Q51038562 | ||
| C4d-positive chronic rejection: a frequent entity with a poor outcome. | Q51722871 | ||
| Indirect CD4+ TH1 response, antidonor antibodies and diffuse C4d graft deposits in long-term recipients conditioned by donor antigens priming. | Q51736671 | ||
| Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. | Q54469292 | ||
| New evidence for a role of allograft accommodation in long-term tolerance. | Q54571630 | ||
| Genetics of the blood transfusion effect on heart allografts in rats | Q70365718 | ||
| Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection | Q74644326 | ||
| Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN') | Q79921621 | ||
| Rituximab therapy for acute humoral rejection after kidney transplantation | Q80318231 | ||
| Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients | Q81630882 | ||
| Differential expression of profibrotic and growth factors in chronic allograft nephropathy | Q82547242 | ||
| T cells lacking immunoproteasome subunits MECL-1 and LMP7 hyperproliferate in response to polyclonal mitogens | Q82878854 | ||
| C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats | Q83149343 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunoproteasome | Q106087471 |
| P304 | page(s) | 880-890 | |
| P577 | publication date | 2010-02-24 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection | |
| P478 | volume | 77 |
| Q38223778 | Biological pathways and potential targets for prevention and therapy of chronic allograft nephropathy |
| Q42913151 | Bortezomib: a new player in pre- and post-transplant desensitization? |
| Q37931981 | Clinical and investigational use of proteasome inhibitors for transplant rejection |
| Q27027082 | Effector mechanisms of rejection |
| Q34663943 | Expression of miR-142-5p in peripheral blood mononuclear cells from renal transplant patients with chronic antibody-mediated rejection |
| Q53095749 | Kidney international web focus on transplantation. |
| Q27006030 | Late and chronic antibody-mediated rejection: main barrier to long term graft survival |
| Q53782591 | Living-donor kidney transplantation with existing anti-donor specific antibodies at a Japanese single center. |
| Q28822270 | Mining kidney toxicogenomic data by using gene co-expression modules |
| Q26830410 | Proteasome inhibitor-based therapy for antibody-mediated rejection |
| Q38544617 | Relationship among C1q-fixing de novo donor specific antibodies, C4d deposition and renal outcome in transplant glomerulopathy. |
| Q35171759 | Sequence capture and next generation resequencing of the MHC region highlights potential transplantation determinants in HLA identical haematopoietic stem cell transplantation |
| Q51768026 | TNF blockade abrogates the induction of T cell-dependent humoral responses in an allotransplantation model. |
| Q37888770 | Targeting B cells and antibody in transplantation |
Search more.